According to regulatory disclosures from the Ho Chi Minh City Stock Exchange (HoSE), Vimedimex Medi-Pharma Joint Stock Company (Ticker: VMD) has received consecutive resignation letters from a wave of high-level executives spanning its Board of Directors and Supervisory Committee for the 2022–2027 tenure. This sudden corporate exodus materializes immediately prior to the opening of the company’s 2026 Annual General Meeting (AGM) and follows a formal compliance warning issued by exchange regulators over delayed financial reporting.
The documented executive departures, annual meeting agendas, and regulatory disclosure infractions feature:
-
Systemic Executive Resignations Across Governance Organs:
-
Board of Directors Retraction: Lê Tiến Dũng has formally submitted his resignation from his seat on the Board of Directors for the 2022–2027 term. Within the disclosure, Dũng noted that unexpected personal reasons left him with insufficient time to properly execute his strategic oversight roles and responsibilities at the pharma firm.
-
Supervisory Committee Dissolution: Concurrently, Vimedimex received separate, simultaneous resignation files from the entire leadership block of its Supervisory Committee for the 2022–2027 tenure, all citing personal reasons. The retractions involve Đoàn Đức Giang (Head and Member of the Supervisory Committee) alongside two standing committee members, Nguyễn Thanh Thanh Bình and Trương Duy Phong.
-
-
Scheduling Parameters and Operational Agendas for the 2026 AGM:
-
Logistics: The pharmaceutical enterprise scheduled its annual shareholder convention to commence at 8:30 AM on June 12, 2026, hosted at the Hanoi Daewoo Hotel (Hanoi). Eligible participants encompass all equity holders validated on VMD’s official shareholder registry as of the definitive record date on May 15, 2026.
-
Agenda Frameworks: During the assembly, Vimedimex executives are slated to present key operational dossiers for shareholder ratification, including the 2025 corporate performance summary, strategic business targets for fiscal year 2026, the 2025 Board of Directors evaluation report, independent board member reviews, and the audited full-year 2025 financial statements.
-
-
Regulatory Sanctions and Disclosure Compliance Warnings by HoSE:
-
Preceding this leadership shakeup, HoSE dispatched an official written warning to Vimedimex management during early May 2026 regarding its failure to comply with statutory financial publication timelines.
-
As of May 6, 2026, the company had crossed the regulatory deadline without publishing its Q1/2026 financial statements (covering both standalone and consolidated ledgers) in either Vietnamese or English as mandated by securities law. Consequently, HoSE ordered Vimedimex to strictly execute its information disclosure obligations to safeguard the equitable rights of public shareholders and preserve capital market transparency.
-